OncoMatch/Leukemia — Acute Myeloid (AML)/TP53
Leukemia — Acute Myeloid (AML)TP53 Clinical Trials
TP53 mutations occur in 5–10% of AML and are strongly associated with complex karyotype, therapy-related AML, and very poor prognosis with standard therapies. No agent is yet specifically approved for TP53-mutant AML, though eprenetapopt (APR-246) and decitabine/cedazuridine combinations have been studied. Trials evaluate novel p53-reactivating agents, hypomethylating regimens, and allogeneic transplant strategies for this high-risk population.
Top recruiting TP53 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count. See all 21 trials matched to your profile →
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc.
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota